Drugs / Rimiducid
Rimiducid
Trials 18 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 21 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT07553390 Background | Oct 2026 → Mar 2036 expected | breast cancer | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06984341 Background | Jun 2026 → Nov 2033 expected | systemic lupus erythematosus | Genentech, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06014762 Background | Apr 2024 → Mar 2029 expected | high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Poseida Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06066424 Background | Oct 2023 → Apr 2038 expected | cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04960579 Background | May 2022 → Mar 2029 expected | plasma cell myeloma | Poseida Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05239143 Background | Feb 2022 → Apr 2026 overdue | breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma +5 | Poseida Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04249947 Background | Feb 2020 → Sep 2024 | adenoid cystic carcinoma, castration-resistant prostate carcinoma, mucoepidermoid carcinoma, salivary duct carcinoma +1 | Poseida Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03807063 Background | Jan → Dec 2020 | B-cell chronic lymphocytic leukemia, CD4+/CD56+ hematodermic neoplasm, acute biphenotypic leukemia, bilineal acute myeloid leukemia +4 | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT03958656 Background | Jun 2019 → Oct 2020 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03741127 Background | Oct 2018 → Aug 2032 expected | plasma cell myeloma | Poseida Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02792114 Background | Jun 2016 → Jun 2027 expected | Her2-receptor negative breast cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01823978 Background | Apr 2013 → May 2016 | castration-resistant prostate carcinoma | Bellicum Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07509008 Background | Sep 2026 → Jul 2028 expected | gastric adenocarcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07598955 Background | Mar 2026 → Jun 2027 expected | thymic carcinoma, thymoma | Beijing Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03288493 Background | Sep 2017 → Apr 2022 | plasma cell myeloma | Poseida Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03056339 Background | Jun 2017 → Mar 2023 | B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03733249 Background | Jan 2017 → Jun 2020 | Diamond-Blackfan anemia, Fanconi anemia, acute lymphoblastic leukemia, childhood acute myeloid leukemia +5 | Bellicum Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07164469 Background | Dec 2026 → Sep 2031 expected | Hodgkins lymphoma, large B-cell lymphoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03699475 Background | Dec 2018 → Jul 2019 | acute myeloid leukemia, myelodysplastic syndrome | Bellicum Pharmaceuticals | Terminated | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT03594162 Background | — | acute lymphoblastic leukemia, immunoproliferative disorder | UNC Lineberger Comprehensive Cancer Center | No longer available | No outcome recorded |
| — | NCT03639844 Background | — | Hurler syndrome, metachromatic leukodystrophy | Bellicum Pharmaceuticals | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rimiducid | “chemical inducer of dimerization (CID; AP1903/Rimiducid)” PMID 25977584 ↗ May 201527“Drug: rimiducid” NCT03699475 ↗ |
| Known as | AP1903 | “Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is...” NCT02065869 ↗16“A single dose of a small-molecule drug (AP1903) eliminated more than 90 % of the modified T cells within 30 min after administration and symptoms resolved without recurrence.” PMID 26072403 ↗ 2015 “the safety of Rimiducid (AP1903) on day 7 to prevent GVHD” NCT02231710 ↗ “Rimiducid (AP1903)” NCT07598955 ↗ “Rimiducid (AP1903)” NCT07509008 ↗ “Rimiducid (AP1903)” NCT07164469 ↗ |
| Known as | AP1903 Dimerizer Drug | “AP1903 Dimerizer Drug” NCT01494103 ↗ |
| Action | Activate | “The drug (AP1903) that will be used to "activate" the iCasp9” NCT00710892 ↗ |
| Modality | Small molecule | “A single dose of a small-molecule drug (AP1903)” PMID 26072403 ↗ 2015 |
| Route | Intravenous | “This drug will be given as a 2-hour intravenous infusion.” NCT00710892 ↗ |